17,261 trials
Eczema · Allergy Symptoms · Psoriasis
Primary: Number of Participants With Incorrect Duration of Use of the Medication — 97; 89 Participants
Migraine Without Aura
Primary: Headache Relief (Modified LOCF - Efficacy Evaluable Analysis Set) — 42; 30 Participants
Non-Small Cell Lung Cancer
Primary: Time to Disease Progression or Death by Line of Treatment — 3.4; 4.7; 2.7; 3.9 months
Non-small Cell Lung Cancer
Primary: Progression-free Survival — 8.95 Months
Myelodysplastic Syndrome (MDS) · Acute Myeloid Leukemia (AML) · Chronic Myeloid Leukemia (CML)
Primary: Number of Participants Who Experienced Inducing or Boosting of a Cellular Immune Response — 5; 2 participants
Leukemia, Myeloid
Primary: Response Rate (CR + CRi + LFS) — 3; 10 participants
Non-Small Cell Lung Cancer
Primary: Percentage of Participants With Non-Progression at Week 8 as Assessed by Response Evaluation Criteria in Solid Tumors (RECIST) — 76.9; 80.3 percentage of participants
Chronic Hepatitis C
Primary: Sustained Virologic Response (SVR) — 27; 29 Number of participants with SVR
Cytomegalovirus Infections
Primary: Cellular Immune Response in Vaccine Recipients — 14 participants
Myelodysplastic Syndrome · Acute Myeloid Leukemia (AML) · Chronic Myeloid Leukemia (CML)
Primary: Cellular Immune Response — 4 participants
Adenocarcinoma of the Prostate · Recurrent Prostate Cancer · Stage I Prostate Cancer
Primary: PSA Response Rate With Bevacizumab Therapy in Androgen Independent Non-metastatic Prostate Cancer — 5 participants
Esophageal Cancer · Gastric Cancer
Primary: Time to Progression — 6.6 months
Aging
Primary: Delay Eyeblink Conditioning — 52.32; 56.88 percentage of conditioned responses
Myocardial Reperfusion Injury
Primary: Average Peak Velocity (APV) Immediately Following Percutaneous Coronary Intervention (PCI) — 30; 19 cm/s — p=0.029
Acute Lymphoblastic Leukemia · ALL · Acute Myelogenous Leukemia
Primary: Rate of Dose Limiting Toxicities — 0.045 proportion of participants of DLT